Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Marta Szajnik, Małgorzata Czystowska-Kuźmicz, Esther Elishaev & Theresa L. Whiteside. (2016) Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Review of Molecular Diagnostics 16:8, pages 811-826.
Read now
Read now
Rene Cortese, Lei Lu, Yueyue Yu, Douglas Ruden & Erika C. Claud. (2016) Epigenome-Microbiome crosstalk: A potential new paradigm influencing neonatal susceptibility to disease. Epigenetics 11:3, pages 205-215.
Read now
Read now
Jane Borley & Robert Brown. (2015) Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Annals of Medicine 47:5, pages 359-369.
Read now
Read now
Holger Heyn, Jesús Méndez-González & Manel Esteller. (2013) Epigenetic profiling joins personalized cancer medicine. Expert Review of Molecular Diagnostics 13:5, pages 473-479.
Read now
Read now
Victor V Levenson. (2010) DNA methylation as a universal biomarker. Expert Review of Molecular Diagnostics 10:4, pages 481-488.
Read now
Read now
Articles from other publishers (30)
Kaiyang Song & Mara Artibani. (2023) The role of DNA methylation in ovarian cancer chemoresistance: A narrative review. Health Science Reports 6:5.
Crossref
Crossref
Roshni D Kalachand, Britta Stordal, Stephen Madden, Benjamin Chandler, Julie Cunningham, Ellen L Goode, Ilary Ruscito, Elena I Braicu, Jalid Sehouli, Atanas Ignatov, Herbert Yu, Dionyssios Katsaros, Gordon B Mills, Karen H Lu, Mark S Carey, Kirsten M Timms, Jolanta Kupryjanczyk, Iwona K Rzepecka, Agnieszka Podgorska, Jessica N McAlpine, Elizabeth M Swisher, Sarah S Bernards, Ciaran O’Riain, Sharon O’Toole, John J O’Leary, David D Bowtell, David M Thomas, Katharina Prieske, Simon A Joosse, Linn Woelber, Parvesh Chaudhry, Norman Häfner, Ingo B Runnebaum & Bryan T Hennessy. (2020)
BRCA1
Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
. JNCI: Journal of the National Cancer Institute 112:12, pages 1190-1203.
Crossref
Crossref
Quan Xu, Jin-Cheng Zhai, Cai-Qin Huo, Yang Li, Xue-Jiao Dong, Dong-Fang Li, Ru-Dan Huang, Chuang Shen, Yu-Jun Chang, Xi-Ling Zeng, Fan-Lin Meng, Fang Yang, Wan-Ling Zhang, Sheng-Nan Zhang, Yi-Ming Zhou & Zhi Zhang. (2020) OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level. BMC Cancer 20:1.
Crossref
Crossref
Ran Zhao, Guiling Lin, Yisheng Wang, Wenjun Qin, Tong Gao, Jing Han, Ruihuan Qin, Yiqing Pan, Jie Sun, Changhao Ren, Shifang Ren & Congjian Xu. (2020) Use of the serum glycan state to predict ovarian cancer patients' clinical response to chemotherapy treatment. Journal of Proteomics 223, pages 103752.
Crossref
Crossref
Marta Brunetti, Ioannis Panagopoulos, Francesca Micci & Ben Davidson. (2019)
MGMT
promoter methylation is a rare epigenetic change in malignant effusions
. Cytopathology 31:1, pages 12-15.
Crossref
Crossref
Chunjing Jin, Minfeng Yang, Xueqiao Han, Haidan Chu, Yan Zhang, Meihong Lu, Zhonghui Wang, Xinxin Xu, Wenwen Liu, Feng Wang & Shaoqing Ju. (2019) Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125. Journal of Ovarian Research 12:1.
Crossref
Crossref
Bo Gao, Fengmei Yang, Wei Chen, Rui Li, Xiuxue Hu, Yong Liang & Dongmin Li. (2019) Multidrug resistance affects the prognosis of primary epithelial ovarian cancer. Oncology Letters.
Crossref
Crossref
Vibha Patil & Zdenko Herceg. 2019. Clinical Epigenetics. Clinical Epigenetics
153
171
.
Ruth Pidsley & Clare Stirzaker. 2019. Clinical Epigenetics. Clinical Epigenetics
217
245
.
Jolein Mijnes, Jürgen Veeck, Nadine T. Gaisa, Eduard Burghardt, Tim C. de Ruijter, Sonja Gostek, Edgar Dahl, David Pfister, Sebastian C. Schmid, Ruth Knüchel & Michael Rose. (2018) Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer. Clinical Epigenetics 10:1.
Crossref
Crossref
Xiaoxuan Xia, Haoyi Weng, Ruoting Men, Rui Sun, Benny Chung Ying Zee, Ka Chun Chong & Maggie Haitian Wang. (2018) Incorporating methylation genome information improves prediction accuracy for drug treatment responses. BMC Genetics 19:S1.
Crossref
Crossref
Shoko Vos, Paul Joannes van Diest & Cathy Beatrice Moelans. (2018) A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?. Critical Reviews in Oncology/Hematology 127, pages 29-41.
Crossref
Crossref
Baoli Qiao, Zhenyu Zhang & Yanfang Li. (2018)
Association of
MGMT
promoter methylation with tumorigenesis features in patients with ovarian cancer: A systematic meta-analysis
. Molecular Genetics & Genomic Medicine 6:1, pages 69-76.
Crossref
Crossref
Haller J. Smith, J. Michael Straughn, Donald J. Buchsbaum & Rebecca C. Arend. (2017) Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. Gynecologic Oncology Reports 20, pages 81-86.
Crossref
Crossref
Kun-Hsing Yu, Douglas A. Levine, Hui Zhang, Daniel W. Chan, Zhen Zhang & Michael Snyder. (2016) Predicting Ovarian Cancer Patients’ Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures. Journal of Proteome Research 15:8, pages 2455-2465.
Crossref
Crossref
Nicolette G. Alkema, G. Bea A. Wisman, Ate G.J. van der Zee, Marcel A.T.M. van Vugt & Steven de Jong. (2016) Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resistance Updates 24, pages 55-69.
Crossref
Crossref
Madalene A. Earp & Julie M. Cunningham. (2015) DNA methylation changes in epithelial ovarian cancer histotypes. Genomics 106:6, pages 311-321.
Crossref
Crossref
T. Ignatov, H. Eggemann, S. D. Costa, A. Roessner, T. Kalinski & A. Ignatov. (2014) BRCA1 promoter methylation is a marker of better response to platinum–taxane-based therapy in sporadic epithelial ovarian cancer. Journal of Cancer Research and Clinical Oncology 140:9, pages 1457-1463.
Crossref
Crossref
XUEFENG BAI, YINGZI FU, HUI XUE, KEJUN GUO, ZHIGUO SONG, ZHAOJIN YU, TIANHONG JIA, YUANYUAN YAN, LIN ZHAO, XIAOYI MI, ENHUA WANG, ZHIHONG ZHENG, HAISHAN ZHAO, WEIFAN YAO & MINJIE WEI. (2014) BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases. Oncology Letters 7:4, pages 1088-1096.
Crossref
Crossref
Brian S. Gloss & Goli Samimi. (2014) Epigenetic biomarkers in epithelial ovarian cancer. Cancer Letters 342:2, pages 257-263.
Crossref
Crossref
Marsha Reyngold & Timothy A. Chan. 2015. Molecular Oncology. Molecular Oncology
37
45
.
Susan K. Murphy, Christopher F. Bassil & Zhiqing Huang. 2013. Ovarian Cancer. Ovarian Cancer
67
74
.
Alexandre How Kit, Helene Myrtue Nielsen & Jörg Tost. (2012) DNA methylation based biomarkers: Practical considerations and applications. Biochimie 94:11, pages 2314-2337.
Crossref
Crossref
Frank Roossink, Steven de Jong, G. Bea A. Wisman, Ate G. J. van der Zee & Ed Schuuring. (2012) DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art. Cellular Oncology 35:4, pages 231-241.
Crossref
Crossref
Xuefeng Bai, Zhiguo Song, Yingzi Fu, Zhaojin Yu, Lin Zhao, Haishan Zhao, Weifan Yao, Desheng Huang, Xiaoyi Mi, Enhua Wang, Zhihong Zheng & Minjie Wei. (2012) Clinicopathological Significance and Prognostic Value of DNA Methyltransferase 1, 3a, and 3b Expressions in Sporadic Epithelial Ovarian Cancer. PLoS ONE 7:6, pages e40024.
Crossref
Crossref
Ming-Cheng Chang, Ying-Cheng Chiang, Chih-Ming Ho, Yu-Li Chen, Chi-An Chen, Wen-Fang Cheng & Cheng-Yang Chou. (2012) New primers for methylation-specific polymerase chain reaction enhance specificity of detecting STAT1 methylation. Taiwanese Journal of Obstetrics and Gynecology 51:1, pages 43-49.
Crossref
Crossref
Marieke A. Vollebergh, Jos Jonkers & Sabine C. Linn. (2011) Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cellular and Molecular Life Sciences 69:2, pages 223-245.
Crossref
Crossref
Reza Asadollahi, Caroline A.C. Hyde & Xiao Yan Zhong. (2010) Epigenetics of ovarian cancer: From the lab to the clinic. Gynecologic Oncology 118:1, pages 81-87.
Crossref
Crossref
Curtis Balch, Daniela E Matei, Tim H-M Huang & Kenneth P Nephew. (2010) Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2:3, pages 419-447.
Crossref
Crossref
Timothy A. Chan & Stephen B. Baylin. 2012. Therapeutic Kinase Inhibitors. Therapeutic Kinase Inhibitors
189
216
.